← All diagnostics
AI Impact Diagnostic

Healthcare, pharma and medtech

Pharmaceutical companies, medical devices, digital health, connected wellness, clinical research — SMEs and mid-caps of 10 to 500 employees

What is the impact of AI on healthcare, pharma and medtech?

The healthcare-pharma-medtech sector is living a paradox. On one hand, regulation (market authorisation, CE marking, clinical trials, health data GDPR) slows AI adoption in critical processes. On the other, AI is already revolutionising R&D (molecular discovery, assisted diagnostics, imaging analysis), operational efficiency (regulatory documentation, pharmacovigilance, supply chain) and market access (therapeutic personalisation, medical marketing). SMEs and mid-caps in the sector that don't integrate AI risk being outpaced by more agile competitors — or acquired by large groups that are investing massively.

Exposure score 55% — Moderate to high
Role transformation 55%

Roles analyzed: R&D / Product engineering, Regulatory affairs / Quality, Medical marketing / Sales, Production / Supply chain, Data / Digital, Executive management

Typical profiles: specialised pharmaceutical labs (santispharma.com), innovative medtech (graftys.com), digital health and VR therapies (c2.care), wellness devices (morphee.co), CROs and clinical research organisations

Overall exposure

How to read this grid

Green bar = opportunity to seize The longer it is, the stronger the potential — but action is needed to benefit.
Orange bar = threat to anticipate The longer it is, the higher the risk if nothing is done.

Click any cell to read the detailed explanation of the opportunity and threat.

Hover over column headers to understand what they measure.

Frequently asked questions

What is the impact of AI on healthcare, pharma and medtech?
The healthcare-pharma-medtech sector is living a paradox. On one hand, regulation (market authorisation, CE marking, clinical trials, health data GDPR) slows AI adoption in critical processes. On the other, AI is already revolutionising R&D (molecular discovery, assisted diagnostics, imaging analysis), operational efficiency (regulatory documentation, pharmacovigilance, supply chain) and market access (therapeutic personalisation, medical marketing). SMEs and mid-caps in the sector that don't integrate AI risk being outpaced by more agile competitors — or acquired by large groups that are investing massively.
What is the AI exposure level of this sector?
The overall exposure score is 55% (Moderate to high — heavy regulation but massive transformation potential). This score measures the combination of AI-related threats and opportunities for this sector.
How is AI transforming roles in this sector?
AI transformation of healthcare-pharma-medtech teams is uneven but profound. R&D is the primary beneficiary: accelerated discovery, molecular simulation, clinical trial design. Regulatory affairs save considerable time on documentation. Medical marketing and sales teams access unprecedented targeting and personalisation. And the executive team gains decision-support tools that transform strategic steering. But each function must integrate AI within a strict compliance framework — this is the sector's specificity.
What should businesses do to prepare for AI in this sector?
The main action areas are: Accelerate R&D and regulatory production — the most tangible immediate gain; Enrich the value proposition — from product to integrated solution; Build responsible AI governance — compliance, ethics and trust. Every business is unique — a personalized diagnostic helps identify priorities.

Related sector diagnostics

Real estate agents — transaction and intermediation 58% — High Audiovisual production and content creation 65% — High Specialist installer — home energy comfort and equipment 35% — Moderate Legal professions — lawyers and advisory 65% — High